Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
The ASTCT and CIBMTR to hold a joint meeting » 04:55
02/23/20
02/23
04:55
02/23/20
04:55
ABBV

AbbVie

$94.96 /

+0.7 (+0.74%)

, ADPT

Adaptive Biotechnologies

$34.19 /

+0.37 (+1.09%)

, AMGN

Amgen

$222.80 /

+0.62 (+0.28%)

, ATNM

Actinium Pharmaceuticals

$0.26 /

+0.0088 (+3.50%)

, ATRA

Atara Biotherapeutics

$13.18 /

-0.34 (-2.51%)

, AZN

AstraZeneca

$50.17 /

+1.2 (+2.45%)

, BLUE

Bluebird Bio

$80.15 /

-2.38 (-2.88%)

, CDNA

CareDx

$28.25 /

+0.13 (+0.46%)

, CDTX

Cidara Therapeutics

$3.16 /

+ (+0.00%)

, CELG

Bought by BMY

$0.00 /

+ (+0.00%)

, EQ

Equillium

$5.48 /

+0.38 (+7.45%)

, GMDA

Gamida Cell

$4.55 /

-0.2 (-4.21%)

, GSK

GlaxoSmithKline

$43.11 /

+0.35 (+0.82%)

, HUM

Humana

$369.65 /

-1.9 (-0.51%)

, INCY

Incyte

$80.89 /

-1.88 (-2.27%)

, JAZ

Jazz Technologies

$0.00 /

+ (+0.00%)

, KDMN

Kadmon

$5.08 /

+0.03 (+0.59%)

, MGTA

Magenta Therapeutics

$14.00 /

-0.02 (-0.14%)

, MRK

Merck

$82.34 /

-0.14 (-0.17%)

, NVS

Novartis

$96.75 /

+0.44 (+0.46%)

, PFE

Pfizer

$35.71 /

-0.13 (-0.36%)

, RCKT

Rocket Pharmaceuticals

$22.73 /

-1.01 (-4.25%)

, SGEN

Seattle Genetics

$117.00 /

-1.3 (-1.10%)

, SNY

Sanofi

$50.83 /

+0.07 (+0.14%)

, TAK

Takeda Pharmaceutical

$18.78 /

+0.195 (+1.05%)

American Society for…

American Society for Transplantation & Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR) hold the 2020 TCT: Transplantation & Cellular Therapy Meeting will be held in Orlando on February 19-23.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Saturday
Conference/Events
The ASTCT and CIBMTR to hold a joint meeting » 04:55
02/22/20
02/22
04:55
02/22/20
04:55
ABBV

AbbVie

$94.96 /

+0.7 (+0.74%)

, ADPT

Adaptive Biotechnologies

$34.19 /

+0.37 (+1.09%)

, AMGN

Amgen

$222.80 /

+0.62 (+0.28%)

, ATNM

Actinium Pharmaceuticals

$0.26 /

+0.0088 (+3.50%)

, ATRA

Atara Biotherapeutics

$13.18 /

-0.34 (-2.51%)

, AZN

AstraZeneca

$50.17 /

+1.2 (+2.45%)

, BLUE

Bluebird Bio

$80.15 /

-2.38 (-2.88%)

, CDNA

CareDx

$28.25 /

+0.13 (+0.46%)

, CDTX

Cidara Therapeutics

$3.16 /

+ (+0.00%)

, CELG

Bought by BMY

$0.00 /

+ (+0.00%)

, EQ

Equillium

$5.48 /

+0.38 (+7.45%)

, GMDA

Gamida Cell

$4.55 /

-0.2 (-4.21%)

, GSK

GlaxoSmithKline

$43.11 /

+0.35 (+0.82%)

, HUM

Humana

$369.65 /

-1.9 (-0.51%)

, INCY

Incyte

$80.89 /

-1.88 (-2.27%)

, JAZ

Jazz Technologies

$0.00 /

+ (+0.00%)

, KDMN

Kadmon

$5.08 /

+0.03 (+0.59%)

, MGTA

Magenta Therapeutics

$14.00 /

-0.02 (-0.14%)

, MRK

Merck

$82.34 /

-0.14 (-0.17%)

, NVS

Novartis

$96.75 /

+0.44 (+0.46%)

, PFE

Pfizer

$35.71 /

-0.13 (-0.36%)

, RCKT

Rocket Pharmaceuticals

$22.73 /

-1.01 (-4.25%)

, SGEN

Seattle Genetics

$117.00 /

-1.3 (-1.10%)

, SNY

Sanofi

$50.83 /

+0.07 (+0.14%)

, TAK

Takeda Pharmaceutical

$18.78 /

+0.195 (+1.05%)

American Society for…

American Society for Transplantation & Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR) hold the 2020 TCT: Transplantation & Cellular Therapy Meeting will be held in Orlando on February 19-23.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Friday
Hot Stocks
Bristol-Myers: Japan's MHLW approves Opdivo for treatment of esophageal cancer » 07:14
02/21/20
02/21
07:14
02/21/20
07:14
BMY

Bristol-Myers

$65.18 /

-0.505 (-0.77%)

Bristol-Myers Squibb…

Bristol-Myers Squibb announced Japan's Ministry of Health, Labor and Welfare has approved Opdivo for the treatment of patients with unresectable advanced or recurrent esophageal cancer that has progressed following chemotherapy.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
The ASTCT and CIBMTR to hold a joint meeting » 04:55
02/21/20
02/21
04:55
02/21/20
04:55
ABBV

AbbVie

$94.26 /

+0.13 (+0.14%)

, ADPT

Adaptive Biotechnologies

$33.82 /

+0.28 (+0.83%)

, AMGN

Amgen

$222.18 /

-0.94 (-0.42%)

, ATNM

Actinium Pharmaceuticals

$0.25 /

+0.0011 (+0.44%)

, ATRA

Atara Biotherapeutics

$13.52 /

-1.23 (-8.34%)

, AZN

AstraZeneca

$48.97 /

-0.34 (-0.69%)

, BLUE

Bluebird Bio

$82.53 /

+1.98 (+2.46%)

, CDNA

CareDx

$28.12 /

-0.05 (-0.18%)

, CDTX

Cidara Therapeutics

$3.16 /

-0.01 (-0.32%)

, CELG

Bought by BMY

$0.00 /

+ (+0.00%)

, EQ

Equillium

$5.10 /

+0.04 (+0.79%)

, GMDA

Gamida Cell

$4.75 /

+ (+0.00%)

, GSK

GlaxoSmithKline

$42.76 /

+0.4688 (+1.11%)

, HUM

Humana

$371.55 /

-7.115 (-1.88%)

, INCY

Incyte

$82.77 /

+0.32 (+0.39%)

, JAZ

Jazz Technologies

$0.00 /

+ (+0.00%)

, KDMN

Kadmon

$5.05 /

-0.085 (-1.66%)

, MGTA

Magenta Therapeutics

$14.02 /

+0.91 (+6.94%)

, MRK

Merck

$82.48 /

+0.48 (+0.59%)

, NVS

Novartis

$96.31 /

-0.98 (-1.01%)

, PFE

Pfizer

$35.84 /

-0.39 (-1.08%)

, RCKT

Rocket Pharmaceuticals

$23.74 /

-0.26 (-1.08%)

, SGEN

Seattle Genetics

$118.30 /

-1.6 (-1.33%)

, SNY

Sanofi

$50.76 /

+0.06 (+0.12%)

, TAK

Takeda Pharmaceutical

$18.59 /

-0.43 (-2.26%)

American Society for…

American Society for Transplantation & Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR) hold the 2020 TCT: Transplantation & Cellular Therapy Meeting will be held in Orlando on February 19-23.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Thursday
Recommendations
Veeva set up for 'clean' beat and raise Q4 report, says Morgan Stanley » 08:55
02/20/20
02/20
08:55
02/20/20
08:55
VEEV

Veeva

$164.19 /

+2.12 (+1.31%)

, IQV

Iqvia

$164.47 /

-0.86 (-0.52%)

Morgan Stanley analyst…

Morgan Stanley analyst Stan Zlotsky said investor concerns that Veeva's (VEEV) large market share and competitive moat in its commercial cloud business could be under pressure from Iqvia (IQV) appear overblown, as his checks have been positive on the competitive advantage Veeva still enjoys. The analyst, who views Veeva's recent ramp in hiring as a sign of the opportunity pipeline management sees heading into FY21, thinks the company is set up for a "clean" beat and raise quarterly report. He maintains an Overweight rating with a $175 price target on Veeva shares ahead of the company's report on March 3.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Eli Lilly management to meet with UBS » 08:50
02/20/20
02/20
08:50
02/20/20
08:50
LLY

Eli Lilly

$140.78 /

-0.23 (-0.16%)

Meetings to be held in…

Meetings to be held in London, England on February 24-25 hosted by UBS.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Compugen to initiate Phase 1/2 triple combination study with Bristol-Myers » 07:07
02/20/20
02/20
07:07
02/20/20
07:07
CGEN

Compugen

$9.83 /

+0.68 (+7.43%)

, BMY

Bristol-Myers

$65.69 /

-0.375 (-0.57%)

Compugen (GEN) announced…

Compugen (GEN) announced its plan to initiate a Phase 1/2 study evaluating a triple combination of Compugen's COM701, an investigational anti-PVRIG antibody, in combination with Bristol-Myers Squibb's (BMY) PD-1 immune checkpoint inhibitor Opdivo and BMS-986207, Bristol-Myers Squibb's investigational anti-TIGIT antibody. The triple combination study is designed to evaluate the blockade of the three immune checkpoint pathways - PVRIG, TIGIT and PD-1, and will accelerate the clinical evaluation of Compugen's science-driven DNAM axis hypothesis in various advanced solid tumors. The study is expected to commence in the second half of 2020, following the clearance of a new Investigational New Drug Application by the U.S. FDA. Compugen will be the study sponsor with Opdivo and BMS-986207 supplied by Bristol-Myers Squibb.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
The ASTCT and CIBMTR to hold a joint meeting » 04:55
02/20/20
02/20
04:55
02/20/20
04:55
ABBV

AbbVie

$94.13 /

+0.53 (+0.57%)

, ADPT

Adaptive Biotechnologies

$33.54 /

+1.79 (+5.64%)

, AMGN

Amgen

$223.12 /

+1.38 (+0.62%)

, ATNM

Actinium Pharmaceuticals

$0.25 /

+0.0041 (+1.67%)

, ATRA

Atara Biotherapeutics

$14.75 /

+0.2 (+1.37%)

, AZN

AstraZeneca

$49.31 /

+0.14 (+0.28%)

, BLUE

Bluebird Bio

$80.55 /

-7.61 (-8.63%)

, CDNA

CareDx

$28.17 /

+1.02 (+3.76%)

, CDTX

Cidara Therapeutics

$3.17 /

+0.09 (+2.92%)

, CELG

Bought by BMY

$0.00 /

+ (+0.00%)

, EQ

Equillium

$5.06 /

+0.02 (+0.40%)

, GMDA

Gamida Cell

$4.75 /

-0.01 (-0.21%)

, GSK

GlaxoSmithKline

$43.49 /

-0.06 (-0.14%)

, HUM

Humana

$378.67 /

+6.41 (+1.72%)

, INCY

Incyte

$82.45 /

+3.2 (+4.04%)

, JAZ

Jazz Technologies

$0.00 /

+ (+0.00%)

, KDMN

Kadmon

$5.13 /

+0.285 (+5.88%)

, MGTA

Magenta Therapeutics

$13.11 /

+0.55 (+4.38%)

, MRK

Merck

$82.00 /

-0.46 (-0.56%)

, NVS

Novartis

$97.29 /

+0.08 (+0.08%)

, PFE

Pfizer

$36.23 /

-0.08 (-0.22%)

, RCKT

Rocket Pharmaceuticals

$24.00 /

-1.18 (-4.69%)

, SGEN

Seattle Genetics

$119.90 /

-0.09 (-0.08%)

, SNY

Sanofi

$50.70 /

-0.44 (-0.86%)

, TAK

Takeda Pharmaceutical

$19.02 /

-0.135 (-0.70%)

American Society for…

American Society for Transplantation & Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR) hold the 2020 TCT: Transplantation & Cellular Therapy Meeting will be held in Orlando on February 19-23.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Wednesday
Conference/Events
The ASTCT and CIBMTR to hold a joint meeting » 08:09
02/19/20
02/19
08:09
02/19/20
08:09
ABBV

AbbVie

$93.60 /

-0.47 (-0.50%)

, ADPT

Adaptive Biotechnologies

$31.75 /

+0.29 (+0.92%)

, AMGN

Amgen

$221.74 /

-1.58 (-0.71%)

, ATNM

Actinium Pharmaceuticals

$0.25 /

-0.0132 (-5.09%)

, ATRA

Atara Biotherapeutics

$14.55 /

+0.3 (+2.11%)

, AZN

AstraZeneca

$49.17 /

+1.3 (+2.72%)

, BLUE

Bluebird Bio

$88.16 /

-0.98 (-1.10%)

, CDNA

CareDx

$27.15 /

+0.48 (+1.80%)

, CDTX

Cidara Therapeutics

$3.08 /

+0.1 (+3.36%)

, CELG

Bought by BMY

$0.00 /

+ (+0.00%)

, EQ

Equillium

$5.04 /

+0.06 (+1.20%)

, GMDA

Gamida Cell

$4.76 /

+0.035 (+0.74%)

, GSK

GlaxoSmithKline

$43.55 /

-0.19 (-0.43%)

, HUM

Humana

$372.26 /

-3.815 (-1.01%)

, INCY

Incyte

$79.25 /

+0.83 (+1.06%)

, JAZ

Jazz Technologies

$0.00 /

+ (+0.00%)

, KDMN

Kadmon

$4.85 /

+0.325 (+7.19%)

, MGTA

Magenta Therapeutics

$12.56 /

+0.2 (+1.62%)

, MRK

Merck

$82.46 /

-0.18 (-0.22%)

, NVS

Novartis

$97.21 /

-0.465 (-0.48%)

, PFE

Pfizer

$36.31 /

-0.18 (-0.49%)

, RCKT

Rocket Pharmaceuticals

$25.18 /

+1.18 (+4.92%)

, SGEN

Seattle Genetics

$119.99 /

+1.9 (+1.61%)

, SNY

Sanofi

$51.14 /

+1.21 (+2.42%)

, TAK

Takeda Pharmaceutical

$19.15 /

-0.29 (-1.49%)

American Society for…

American Society for Transplantation & Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR) hold the 2020 TCT: Transplantation & Cellular Therapy Meeting will be held in Orlando on February 19-23.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Downgrade
Five Prime downgraded to Neutral at Wedbush as cabiralizumab study flops » 07:45
02/19/20
02/19
07:45
02/19/20
07:45
FPRX

Five Prime

$4.42 /

-0.11 (-2.43%)

, BMY

Bristol-Myers

$66.06 /

-0.32 (-0.48%)

As previously reported,…

As previously reported, Wedbush analyst Robert Driscoll downgraded Five Prime (FPRX) to Neutral from Outperform with a price target of $5, down from $12. The analyst cited the announcement that the Phase 2 cabiralizumab study in pancreatic cancer did not meet its primary endpoint. Driscoll is "disappointed" in this result given the rationale behind CSF1-R antagonism as well as the initial signal efficacy observed in pancreatic cancer patients in the prior Phase 1 study. Given that partner Bristol-Myers Squibb (BMY) will no longer directly support development of cabiralizumab, he now sees little to no value in the asset and are removing the program from his model.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.